PreciseDx
Current standards of care in oncology can be subjective, leading to a high percentage of tumors receiving intermediate grading.
$11M Series B+ ·
Led by Eventide · Source: citybiz.co
Total raised: $42.45M across 3 sourced rounds
All 3 rounds ↓Signals
About PreciseDx
As a result, many patients are forced to anxiously await the results of gene expression testing for over a month, delaying vital decisions regarding their care plan.
PreciseDx | 1770 days on the record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $11M | citybiz.co | ||
| Series B+ | $20.7M | startupintros.com | ||
| Series A | $10.75M | fundraisingfox.com |
Timeline
- Website created
Founders and team
CC
Carlos Cordon-Cardo Foundersource: precisedx.aiGF
Gerardo Fernandez Co-Foundersource: precisedx.aiJZ
Jack Zeineh FounderMD
Michael Donovan Co-Foundersource: precisedx.aiEC
Eric Converse CEOWB
Wayne Brinster President & CEOBG
Bradley Gendell Chief Financial OfficerES
Ed Sitar Chief Financial Officer
Investors
- AAgilent Technologies
EEventidelead investor
GGenHenn Venture
IIBM Ventures
LLabCorp
MMerck Global Health Innovation Fundlead investor
- MMount Sinai Health System
PPhilips Health Technology Ventures
QQuest Diagnostics
Companies like PreciseDx
RRondo Therapeutics$67M Series A · Mar 2022
AAkamis Bio$60M Series A · Dec 2024
VVocal ClarityOOratos AIPre Seed · Jul 2026
AAlithea Genomics$8.9M Seed · Mar 2026
RRigernaSeed · Mar 2026
Other companies backed by Eventide
AAdvanCell$315M Series B+ · Jul 2026
LLeo Cancer Care$65M Series B+ · Jul 2026
FFlare Therapeutics$85M Series B+ · Jun 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/precisedx (get a free API key).